Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588028 | 0.76 | HSD17B10 (0.41) | KMT2AALDH1A1ALOX15SMN1; SMN2POLB | |
| SCHEMBL27993511 | 0.73 | L3MBTL1 (0.44) | KMT2AL3MBTL1ALDH1A1ALOX15CYP1A2 | |
| SCHEMBL29955328 | 0.72 | HSP90AA1 (0.39) | KMT2AL3MBTL1ALDH1A1TP53TDP1 | |
| SCHEMBL28435187 | 0.72 | ENPP2 (0.30) | — | |
| SCHEMBL21555682 | 0.72 | KMT2A (0.44) | KMT2AL3MBTL1ALDH1A1ALOX15CYP1A2 | |
| SCHEMBL483937 | 0.70 | — | — | |
| SCHEMBL28257547 | 0.70 | L3MBTL1 (0.45) | KMT2AL3MBTL1ALDH1A1ALOX15CYP1A2 | |
| SCHEMBL161241 | 0.70 | — | — | |
| SCHEMBL38507 | 0.70 | L3MBTL1 (0.45) | KMT2AL3MBTL1ALDH1A1ALOX15CYP1A2 | |
| SCHEMBL2216802 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | claimed |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-111146496-B | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池股份有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2020-11-05 | — | — | US | disclosed |
| CN-111146496-A | Polymer electrolyte and lithium ion battery containing same | 珠海冠宇电池有限公司 | 2020-05-12 | — | — | CN | disclosed |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-24 | — | — | US | disclosed |
| WO-2015191630-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-12-17 | — | — | WO | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2496557-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| EP-2496557-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GlaxoSmithKline LLC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120141384-A1 | ANTIBACTERIAL CONJUGATED BORONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
| US-20120141384-A1 | ANTIBACTERIAL CONJUGATED BORONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2012-06-07 | — | — | US | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | KMT2A 4408/4885L3MBTL1 4616/4885ALDH1A1 530/4885 |
| US-20120141384-A1 | ANTIBACTERIAL CONJUGATED BORONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABCB11, SLC10A2, SLC10A1 | KMT2A 3669/4885L3MBTL1 1448/4885ALDH1A1 2823/4885 |
| US-20200347021-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | KMT2A 942/4885L3MBTL1 4109/4885ALDH1A1 4541/4885 |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | KMT2A 1698/4885L3MBTL1 4865/4885ALDH1A1 852/4885 |
| US-11447453-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | KMT2A 942/4885L3MBTL1 4109/4885ALDH1A1 4541/4885 |
| US-20230113588-A1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | GRM3, GRM2, GRM1 | KMT2A 942/4885L3MBTL1 4109/4885ALDH1A1 4541/4885 |
| US-10597367-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | KMT2A 942/4885L3MBTL1 4109/4885ALDH1A1 4541/4885 |
| US-12637436-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof | GRM3, GRM2, GRM1 | KMT2A 1325/4885L3MBTL1 4781/4885ALDH1A1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.